Terms: = Pancreatic cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Treatment
77 results:
1. Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity.
Zaremba-Pataj E; Patkowska E; Krzywdzińska A; Szumera-Ciećkiewicz A; Chlebowska-Tuz J
J Hematop; 2023 Mar; 16(1):39-47. PubMed ID: 38175371
[TBL] [Abstract] [Full Text] [Related]
2. BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
Wu Y; Zehnle PMA; Rajak J; Koleci N; Andrieux G; Gallego-Villar L; Aumann K; Boerries M; Niemeyer CM; Flotho C; Bohler S; Erlacher M
Leukemia; 2024 Jan; 38(1):136-148. PubMed ID: 37945692
[TBL] [Abstract] [Full Text] [Related]
3. Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
Ratti F; Marino R; Olthof PB; Pratschke J; Erdmann JI; Neumann UP; Prasad R; Jarnagin WR; Schnitzbauer AA; Cescon M; Guglielmi A; Lang H; Nadalin S; Topal B; Maithel SK; Hoogwater FJH; Alikhanov R; Troisi R; Sparrelid E; Roberts KJ; Malagò M; Hagendoorn J; Malik HZ; Olde Damink SWM; Kazemier G; Schadde E; Charco R; de Reuver PR; Groot Koerkamp B; Aldrighetti L;
Hepatology; 2024 Feb; 79(2):341-354. PubMed ID: 37530544
[TBL] [Abstract] [Full Text] [Related]
4. Bcl-2 family inhibitors sensitize human cancer models to therapy.
Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
[TBL] [Abstract] [Full Text] [Related]
5. Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors.
Yang B; Quan Y; Zhao W; Ji Y; Yang X; Li J; Li Y; Liu X; Wang Y; Li Y
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2169282. PubMed ID: 36656085
[TBL] [Abstract] [Full Text] [Related]
6. The antitumor effect of the novel agent mcl/ACT001 in pancreatic ductal adenocarcinoma.
Yang J; Li Y; Han X; Pei X; Lin Z; Li C
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5717-5728. PubMed ID: 36547690
[TBL] [Abstract] [Full Text] [Related]
7. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
[TBL] [Abstract] [Full Text] [Related]
8. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
9. Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Masuda Y
J Chemother; 2023 Sep; 35(5):435-447. PubMed ID: 36134604
[TBL] [Abstract] [Full Text] [Related]
10. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.
Ling X; Wu W; Aljahdali IAM; Liao J; Santha S; Fountzilas C; Boland PM; Li F
Clin Transl Med; 2022 May; 12(5):e881. PubMed ID: 35604033
[TBL] [Abstract] [Full Text] [Related]
11. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises pancreatic cancer Cells to TRAIL-induced Cell Death.
Ruff JP; Kretz AL; Kornmann M; Henne-Bruns D; Lemke J; Traub B
Anticancer Res; 2021 Dec; 41(12):5973-5985. PubMed ID: 34848451
[TBL] [Abstract] [Full Text] [Related]
12. Overcoming Gemcitabine Resistance in pancreatic cancer Using the BCL-X
Thummuri D; Khan S; Underwood PW; Zhang P; Wiegand J; Zhang X; Budamagunta V; Sobh A; Tagmount A; Loguinov A; Riner AN; Akki AS; Williamson E; Hromas R; Vulpe CD; Zheng G; Trevino JG; Zhou D
Mol Cancer Ther; 2022 Jan; 21(1):184-192. PubMed ID: 34667112
[TBL] [Abstract] [Full Text] [Related]
13. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, mcl-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.
Li F; Aljahdali IAM; Zhang R; Nastiuk KL; Krolewski JJ; Ling X
J Exp Clin Cancer Res; 2021 Aug; 40(1):254. PubMed ID: 34384473
[TBL] [Abstract] [Full Text] [Related]
14. Novel Semi-Synthetic Cu (II)-Cardamonin Complex Exerts Potent Anticancer Activity against Triple-Negative Breast and pancreatic cancer Cells via Inhibition of the Akt Signaling Pathway.
Hossan MS; Break MKB; Bradshaw TD; Collins HM; Wiart C; Khoo TJ; Alafnan A
Molecules; 2021 Apr; 26(8):. PubMed ID: 33918814
[TBL] [Abstract] [Full Text] [Related]
15. Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells.
Aburjania Z; Whitt JD; Jang S; Nadkarni DH; Chen H; Rose JB; Velu SE; Jaskula-Sztul R
Molecules; 2020 Oct; 25(21):. PubMed ID: 33114525
[TBL] [Abstract] [Full Text] [Related]
16. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
[TBL] [Abstract] [Full Text] [Related]
17. mcl-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma.
Castillo L; Young AIJ; Mawson A; Schafranek P; Steinmann AM; Nessem D; Parkin A; Johns A; Chou A; Law AMK; Lucas MC; Murphy KJ; Deng N; Gallego-Ortega D; Caldon CE; ; Timpson P; Pajic M; Ormandy CJ; Oakes SR
Oncogene; 2020 Feb; 39(8):1821-1829. PubMed ID: 31735913
[TBL] [Abstract] [Full Text] [Related]
18. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
[TBL] [Abstract] [Full Text] [Related]
19. Co-Delivery of Gemcitabine and mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in pancreatic cancer.
Wang Y; Gao F; Jiang X; Zhao X; Wang Y; Kuai Q; Nie G; He M; Pan Y; Shi W; Ren S; Yu Q
J Biomed Nanotechnol; 2019 May; 15(5):966-978. PubMed ID: 30890228
[TBL] [Abstract] [Full Text] [Related]
20. miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/mcl-1 Axis.
Liu Y; Lei P; Qiao H; Sun K; Lu X; Bao F; Yu R; Lian C; Li Y; Chen W; Xue F
Int J Biol Sci; 2019; 15(3):579-586. PubMed ID: 30745844
[TBL] [Abstract] [Full Text] [Related]
[Next]
